Rui Ding

Dec 10, 2024 | mdpi.com | Lei Zhang |Rui Ding |Cuiwei Liu |Zhixiang Duan

1. IntroductionDriven by the global energy crisis and the greenhouse effect caused by the burning of fossil fuels, governments around the world are urgently seeking cleaner and renewable energy sources to replace traditional fossil fuels. As technology advances, the commercial exploitation of new energy sources on a large scale has become increasingly feasible.

Jun 22, 2024 | mdpi.com | Jintao Xu |Yang Sui |Tao Yu |Rui Ding

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

May 31, 2024 | cell.com | Rui Ding |Fujian Normal |Yan Wu

Highlights•Tryptophan metabolism of S. woodyi is upregulated in light but inhibited in dark•Interfacial electron transfer upregulates the tryptophan metabolism in light•Lumichrome mediates the upregulation of IAA in tryptophan metabolism•Glycolysis and TCA cycle are upregulated in light, resulting in increased biomassSummaryNon-phototrophic microorganism-semiconductor systems have been designed for solar-to-chemical conversion.

Apr 8, 2024 | dovepress.com | Yuan Huang |Rui Ding |Li Wang |Ji Li

Back to Journals » Cancer Management and Research » Volume 16 Authors Huang Y , Yang H, Ding R , Wang L, Li J, Li W, Qin X, Xu Y, Qian J Received 8 April 2024Accepted for publication 8 July 2024 Published 29 July 2024Volume 2024:16 Pages 921—931 DOI https://doi.org/10.2147/CMAR.S459568Checked for plagiarism YesReview by Single anonymous peer reviewPeer reviewer comments 2 Editor who approved publication: Dr Sanjeev K.

Mar 21, 2024 | sciencedirect.com | Rui Ding |Qiang Zou

Introduction The U.S. Food and Drug Administration (FDA) has approved the combination of nivolumab (Nivo, anti-programmed cell death protein 1 [anti-PD-1]) plus ipilimumab (Ipi, anti-cytotoxic T lymphocyte-associated protein 4 [anti-CTLA-4]) for the treatment of patients with melanoma, colorectal cancer, non-small cell lung cancer, hepatocellular carcinoma, and other cancers.1,2,3,4,5 Although recognized as the most potent and successful immune checkpoint blockade (ICB) combination, serious...